Non viral vectors in gene therapydan overview, J Clin Diagn Res, vol.9, issue.1, pp.1-06, 2015. ,
Nonviral ocular gene therapy: potential ocular therapeutic avenues, Adv Drug Deliv Rev, vol.58, issue.11, pp.1224-1242, 2006. ,
The future looks brighter after 25 years of retinal gene therapy, Hum Gene Ther, vol.28, pp.982-987, 2017. ,
A comprehensive review of retinal gene therapy, Mol Ther, vol.21, issue.3, pp.509-519, 2013. ,
Retinal gene delivery by adeno-associated virus (AAV) vectors: strategies and applications, Eur J Pharm Biopharm, vol.95, pp.343-352, 2015. ,
Vector platforms for gene therapy of inherited retinopathies, Prog Retin Eye Res, vol.43, pp.108-128, 2014. ,
Relevance of assemblyactivating protein for Adeno-associated virus vector production and capsid protein stability in mammalian and insect cells, J Virol, vol.91, pp.1198-01217, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01785930
A viral assembly factor promotes AAV2 capsid formation in the nucleolus, Proc Natl Acad Sci U S A, vol.107, issue.22, pp.10220-10225, 2010. ,
Thermal stability as a determinant of AAV serotype identity, Mol Ther Methods Clin Dev, vol.6, pp.171-182, 2017. ,
AAV-ID: a rapid and robust assay for batch-to-batch consistency evaluation of AAV preparations, Mol Ther, vol.25, issue.6, pp.1375-1386, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01798869
The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability, Nat Protoc, vol.2, issue.9, pp.2212-2221, 2007. ,
In vitro disassembly of a parvovirus capsid and effect on capsid stability of heterologous peptide insertions in surface loops, J Biol Chem, vol.279, issue.8, pp.6517-6525, 2004. ,
AAV vectors for FRET-based analysis of protein-protein interactions in photoreceptor outer segments, Front Neurosci, vol.10, p.356, 2016. ,
Design and development of AAVbased gene supplementation therapies for achromatopsia and retinitis pigmentosa, Methods Mol Biol, vol.1715, pp.33-46, 2018. ,
Accurate identification and quantification of DNA species by next-generation sequencing in adenoassociated viral vectors produced in insect cells, Hum Gene Ther Methods, vol.28, issue.3, pp.148-162, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01607265
High AAV vector purity results in serotype-and tissue-independent enhancement of transduction efficiency, Gene Ther, vol.17, pp.503-510, 2010. ,
Characterization of a recombinant adeno-associated virus type 2 reference standard material, Hum Gene Ther, vol.21, issue.10, pp.1273-1285, 2010. ,
Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2, Gene Ther, vol.6, issue.7, pp.1322-1330, 1999. ,
Practical utilization of recombinant AAV vector reference standards: focus on vector genomes titration by free ITR qPCR, Mol Ther Methods Clin Dev, vol.5, p.16019, 2016. ,
The ReFOLD assay for protein formulation studies and prediction of protein aggregation during long-term storage, Eur J Pharm Biopharm, vol.137, pp.131-139, 2019. ,
Thermal Unfolding of Anti-bodies Comparison of NanoDSF and MDSC for Thermal Stability Assessment During Biopharmaceutical Formulation Development, Nano-TemperTechnol GmbH, 2016. ,
Comparative analysis of adeno-associated virus capsid stability and dynamics, J Virol, vol.87, issue.24, pp.13150-13160, 2013. ,
Methods matterdstandard production platforms for recombinant AAV can produce chemically and functionally distinct vectors, p.640169, 2019. ,
Product-related impurities in clinical-grade recombinant AAV vectors: characterization and risk assessment, Biomedicines, vol.2, issue.1, pp.80-97, 2014. ,
Pharmaceutical development of AAV-based gene therapy products for the eye, Pharm Res, vol.36, issue.2, p.29, 2018. ,
High-throughput melting-temperature analysis of a monoclonal antibody by differential scanning fluorimetry in the presence of surfactants, J Pharm Sci, vol.102, issue.2, pp.415-428, 2013. ,
Thermo-optical protein characterization for straightforward preformulation development, J Pharm Sci, vol.106, issue.10, pp.2955-2958, 2017. ,
Assaying the stability and inactivation of AAV serotype 1 vectors, Hum Gene Ther Methods, vol.28, issue.1, pp.39-48, 2017. ,
Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation, Mol Ther, vol.12, issue.1, pp.171-178, 2005. ,
Key interactions of surfactants in therapeutic protein formulations: a review, Eur J Pharm Biopharm, vol.97, pp.60-67, 2015. ,
Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions, J Pharm Sci, vol.87, issue.12, pp.1554-1559, 1998. ,
AAV empty capsids: for better or for worse?, Mol Ther, vol.22, issue.1, pp.1-2, 2014. ,
Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography, J Virol Methods, vol.140, issue.1-2, pp.183-192, 2007. ,
Removal of empty capsids from type 1 adeno-associated virus vector stocks by anion-exchange chromatography potentiates transgene expression, Mol Ther, vol.13, issue.4, pp.823-828, 2006. ,
Universal method for the purification of recombinant AAV vectors of differing serotypes, Mol Ther Methods Clin Dev, vol.9, pp.33-46, 2018. ,
Analytical ultracentrifugation as an approach to characterize recombinant adeno-associated viral vectors, Hum Gene Ther Methods, vol.26, issue.6, pp.228-242, 2015. ,
Production and characterization of adenoassociated viral vectors, Nat Protoc, vol.1, issue.3, pp.1412-1428, 2006. ,